Literature DB >> 31752499

Psilocybin-assisted therapy for depression: How do we advance the field?

Sally E Meikle1, Paul Liknaitzky2, Susan L Rossell3, Margaret Ross4, Nigel Strauss5, Neil Thomas2,3, Greg Murray2,3, Martin Williams6, David J Castle7,8.   

Abstract

In the quest for new treatment options for depression, attention is being paid to the potential role of psychedelic drugs. Psilocybin is of particular interest given its mechanism of action, its benefits in early trials and its relatively low side effects burden. This viewpoint outlines a number of key issues that remain to be elucidated about its potential use in the clinical environment, including clarification of the profile of people most likely to benefit and those who might experience adverse effects, longer-term outcomes and the role of psychotherapeutic input alongside the drug itself. There are also opportunities to understand better, the neurobiology underpinning its effects.

Entities:  

Keywords:  Psilocybin; depression; psychedelics

Year:  2019        PMID: 31752499     DOI: 10.1177/0004867419888575

Source DB:  PubMed          Journal:  Aust N Z J Psychiatry        ISSN: 0004-8674            Impact factor:   5.744


  2 in total

1.  Restorative Retelling for Processing Psychedelic Experiences: Rationale and Case Study of Complicated Grief.

Authors:  Débora González; Marc B Aixalà; Robert A Neimeyer; Jordi Cantillo; Donald Nicolson; Magi Farré
Journal:  Front Psychol       Date:  2022-05-03

Review 2.  1H Nuclear Magnetic Resonance: A Future Approach to the Metabolic Profiling of Psychedelics in Human Biofluids?

Authors:  Sylvana Vilca-Melendez; Malin V Uthaug; Julian L Griffin
Journal:  Front Psychiatry       Date:  2021-12-13       Impact factor: 4.157

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.